Dibutyryl cyclic AMP was administered to 2 patients with severe congestive heart failure. After an intravenous drip infusion of dibutyryl cyclic AMP (300mg/40min), marked diuresis and mild improvement of the patients' physical activity occurred. The cardiac index increased and both systemic vascular resistance and pulmonary capillary wedge pressure decreased. Blood glucose and plasma insulin increased simultaneously, while plasma free fatty acid decreased during the infusion. A continuous intravenous micro-infusion of dibutyryl cyclic AMP (300mg/24h) also exerted diuresis and improved physical activity. The hemodynamic and metabolic effects of dibutyryl cyclic AMP are expected to be beneficial to a failing heart. hormones, especially catecholamines.1) However, exogenous cyclic AMP does not exert a catecholamine-like effect because it can hardly pass the cell membrane.2) A derivative of cyclic AMP, N6-O2'-dibutyryl cyclic 3', 5' adenosine monophosphate (dibutyryl cyclic AMP), is resistant to enzymatic hydrolysis by phosphodiesterase3) and easily passes through the cell membrane because of its lipid solubility.4) After passing the cell membrane, dibutyryl cyclic AMP is deacylated to cyclic AMP and its accumulation within the cell may result in a catecholamine-like effect,5) or dibutyryl cyclic AMP is deacylated to N6-monobutyryl cyclic AMP, which is a strong
C YCLIC 3', 5' adenosine monophosphate (cyclic AMP) has been shown to play an important role as an intracellular second messenger of various hormones, especially catecholamines.1) However, exogenous cyclic AMP does not exert a catecholamine-like effect because it can hardly pass the cell membrane.2) A derivative of cyclic AMP, N6-O2'-dibutyryl cyclic 3', 5' adenosine monophosphate (dibutyryl cyclic AMP), is resistant to enzymatic hydrolysis by phosphodiesterase3) and easily passes through the cell membrane because of its lipid solubility.4) After passing the cell membrane, dibutyryl cyclic AMP is deacylated to cyclic AMP and its accumulation within the cell may result in a catecholamine-like effect,5) or dibutyryl cyclic AMP is deacylated to N6-monobutyryl cyclic AMP, which is a strong infusion, ascites, hepatomegaly, and edema all decreased and the patient reported improved physical activity (Fig. 3) . Laboratory data showed decreased FFA and unchanged blood glucose and insulin during the micro-in- 
